Naveen Pemmaraju/LinkedIn
Aug 5, 2025, 10:28
Naveen Pemmaraju: Results of A Novel CD123-ADC Pivekimab Sunirine for Patients with BPDCN
Naveen Pemmaraju, Professor of the Department of Leukemia at MD Anderson Cancer Center, shared a post on LinkedIn:
“I was proud to be selected as one of 3 invited faculty to present at our recent MDACC Division of Cancer Medicine annual Best of ASCO Grand Rounds, moderated by Dr Bob Wolff.
I was able to present, on behalf of my co-authors, our work on Results of A Novel CD123-ADC Pivekimab Sunirine for patients with BPDCN.
Thank you, MD Anderson Cancer Center for your continued support and for this key opportunity to present our original work!”
More posts featuring Naveen Pemmaraju on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 5, 2025, 16:07
Aug 5, 2025, 16:04
Aug 5, 2025, 14:16
Aug 5, 2025, 13:23
Aug 5, 2025, 12:52
Aug 5, 2025, 12:39